This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page
Administration and Storage Choosing ReFacto AFChoosing ReFacto AFChoosing ReFacto AFPersonalised dosing On-Demand Use

Menu

Close

Product InformationProduct InformationLaboratory StandardEfficacy & SafetyAdministration & StorageSupport & ResourcesSupport & ResourcesMaterialsVideosOrdering ReFacto AFContact Us

For ReFacto AF® (moroctocog alfa) Prescribing Information for Great Britain and Northern Ireland click here.

Adverse event reporting information can be found at the bottom of the page.

Clinical Efficacy & Safety

​​​​​​ReFacto AF® (moroctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). ReFacto AF® is appropriate for use in adults and children of all ages, including newborns. It does not contain von Willebrand factor, and hence is not indicated in von Willebrand's disease.1

Data supporting the efficacy and safety profile of ReFacto AF®.

 Efficacy

ReFacto AF® is effective for:

Repeated prophylaxis exposure

Prophylactic treatment in previously treated patients (PTPs)


 86%  Reduction in annual bleed rate (ABR) vs. on-demand in previously treated patients (PTPs). ReFacto AF® prophylaxis is more effective at preventing bleeds than on-demand treatment, with an 85% reduction of bleeds per year (median ABR: 3.4; n=154) achieved with prophylactic treatment.2*
 

ReFacto AF® is bioequivalent to ReFacto® and pharmacokinetically equivalent to a full-length recombinant factor VIII (FLrFVIII) comparator,1 so it is expected to behave in the same way.On-demand treatment and Surgery

Prophylactic treatment in PTPs


 73%  of 10,594 bleeding episodes of all degrees of severity were treated effectively with only 1 infusion (n=113).3
 

On-demand treatment in previously untreated patients (PUPs)


 65%  of 2,589 bleeding episodes were treated effectively with only 1 infusion (n=101).3
 

Surgery 


 99.6%  of the infusions administered either during or after surgery were rated as excellent or good by the surgeon and treating physician (38 patients; 48 surgical procedures; 496 infusions during or after surgery).3†

Excellent rating: achievement of comparable haemostasis to that expected after similar surgery in a non-haemophilic patient. Good rating: prolonged time to haemostasis with somewhat increased bleeding compared with that expected after similar surgery in a non-haemophilic patient.3 Safety1

ReFacto AF® has a well-documented safety profile in patients

  • Thrombophlebitis is an uncommon adverse event (≥0.1% to 1%)1
  • FVIII inhibition in PUPs is a very common adverse event (≥10%);1
  • FVIII inhibition in PTPs is an uncommon adverse event (≥0.1& to <1%)1*

Adverse reactions cited as very common(≥10%): FVIII inhibition (PUPs)*, headaches, arthralgia, cough and pyrexia

Adverse reactions cited as common (≥1% to <10%): decreased appetite, dizziness, haemorrhage, haemotoma, diarrhoea, vomiting, abdominal pain, nausea, urticaria, rash, pruritus, myalgia, chills, catheter site related reaction, antibody test positive, anti-factor VIII antibody test positive.

Frequency is based on studies with all FVIII products which included patients with severe haemophilia A.1

For full details on adverse reactions please refer to the Summary of Product Characteristics

Explore More Laboratory StandardsFind out more about the use of Laboratory Standards and patient satisfaction with the ReFacto AF FuseNGo device. Find out moreLoading

Find out more on how to administer and store ReFacto AF using our R2 and FuseNGo devices.

Administration & StorageFind out moreLoadingContact Us

Contact us for more information on ReFacto AF and download our FAQ for supply and stock related queries.

Find out moreLoading

 References 

ReFacto AF® Summary of Product Characteristics. For Great Britain, available here. For Northern Ireland, available here.Parra Lopez R et al. Thromb Haemost. 2015;114(4):676-684Lusher JM et al. Haemophilia 2003;9:38–49.
PP-REF-GBR-0355 July 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​